Publications by L Eichenfield

Publications by authors named "L Eichenfield"

J Drugs Dermatol

December 2024

Topical clindamycin phosphate/adapalene/benzoyl peroxide (CAB) gel is approved for treating acne in patients 12 and older, and post hoc analyses examined its effectiveness in younger patients with acne.
Data from two studies showed that CAB significantly improved treatment success and reduced acne lesions in adolescents compared to a vehicle gel, with 51.5% of treated adolescents achieving success versus 24.9% with the vehicle.
The CAB gel was generally well tolerated, with most adverse events being mild to moderate, and it was effective for younger children as well, with significant lesion reductions observed in all treated children.

Curr Med Res Opin

December 2024

Moderate-to-severe atopic dermatitis (AD) significantly affects patients' quality of life, and advanced systemic therapeutics (AST) like dupilumab and upadacitinib are available but underutilized.
A study of 3,076 patients in the U.S. found that 436 were eligible for AST treatment, and factors like private insurance and disease severity influenced their treatment initiation.
Despite the availability of AST, many patients—47% of adolescents and 58% of adults—remain untreated, highlighting a need for greater advocacy and accessibility for those with severe AD.

Pediatr Dermatol

November 2024

The study aimed to assess long-term infection rates in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis (AD) treated with the medication dupilumab.
It analyzed data from an ongoing open-label extension (OLE) study, showing that long-term dupilumab treatment resulted in lower infection rates compared to previous shorter trials.
The findings indicate that dupilumab treatment is associated with a reduced frequency of infections and is considered safe for young children with AD.

J Dermatolog Treat

December 2024

Baricitinib, a selective Janus kinase inhibitor, showed positive effects on moderate-to-severe atopic dermatitis in children after 16 weeks in the BREEZE-AD-PEDS study.* -
The long-term extension study found that a greater percentage of patients on the 4-mg dose achieved significant skin improvement at 52 weeks compared to lower doses and placebo.* -
Overall, the treatment was mostly safe, with mild to moderate side effects reported and no serious safety issues or new risks identified.*

J Drugs Dermatol

November 2024

Topical CAB gel, a combination of clindamycin phosphate, adapalene, and benzoyl peroxide, is the only approved treatment for moderate-to-severe acne using a triple formulation, showing superior results in clinical studies compared to individual components.
In two phase 3 studies, participants aged 9 and older were treated with CAB or a placebo, resulting in over 70% reduction in acne lesions for all CAB-treated cases by week 12, with most achieving clear skin or a notable reduction in severity.
Overall findings indicated CAB is effective and well-tolerated, emphasizing the need for patient education on adherence and managing expectations regarding side effects.